MedTrace Logo

A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

NCT04571398 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-10-01

No results posted yet for this study

Summary

Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.

Conditions

Interventions

OTHER

ApricityRx mobile application

AE detection and monitoring software

Sponsors & Collaborators

  • Apricity Health, Inc

    lead INDUSTRY

Principal Investigators

  • Brian Henick, MD · Columbia University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2022-10-15
Completion
2023-10-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04571398 on ClinicalTrials.gov